Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single subcutaneous injections of PEG-uricase (4 to 24 mg) were administered to 13 such subjects (11 had tophaceous gout), whose plasma uric acid concentration (pUAc) was 11.3 ± 2.1 mg/dl (mean ± SD). By day seven after injection of PEG-uricase, pUAc had declined by an average of 7.9 mg/dl and had normalized in 11 subjects, whose mean pUAc decreased to 2.8 ± 2.2 mg/dl. At doses of 8, 12, and 24 mg, the mean pUAc at 21 days after injection remained no more than 6 mg/dl. In eight subjects, plasma uricase activity was still measurable at 21 days after injection (half-life 10.5 to 19.9 days). In the other five subjects, plasma uricase activity could not be detected beyond ten days after injection; this was associated with the appearance of relatively low-titer IgM and IgG antibodies against PEG-uricase. Unexpectedly, these antibodies were directed against PEG itself rather than the uricase protein. Three PEG antibody-positive subjects had injection-site reactions at 8 to 9 days after injection. Gout flares in six subjects were the only other significant adverse reactions, and PEG-uricase was otherwise well tolerated. A prolonged circulating life and the ability to normalize plasma uric acid in markedly hyperuricemic subjects suggest that PEG-uricase could be effective in depleting expanded tissue stores of uric acid in subjects with chronic or tophaceous gout. The development of anti-PEG antibodies, which may limit efficacy in some patients, is contrary to the general assumption that PEG is non-immunogenic. PEG immunogenicity deserves further investigation, because it has potential implications for other PEGylated therapeutic agents in clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 Competition ELISA to determine the specificity of IgG antibody against PEG-uricase. Increasing amounts of the indicated materials were added to aliquots of plasma obtained from subject 013 on day 14 after subcutaneous injection of 12 mg of PEG-modified recombinant mammalian urate oxidase (PEG-uricase). After incubation overnight, these mixtures were tested at a 1:60 dilution in the ELISA for IgG antibody against PEG-uricase. (a) 'Uricase' is the unmodified recombinant protein used in PEG-uricase, and 'PEG 10000' is 10 K monomethoxyPEG (mPEG) conjugated with glycine instead of uricase protein. 'PEG-PNP' is bacterial purine nucleoside phosphorylase conjugated with mPEG of molecular mass 5 kDa, prepared as described [18]. (b) 'PEG 350' and 'PEG 2000' are unconjugated, nonactivated mPEGs of molecular masses 350 and 2,000 Da. 'PEG 5000' and 'PEG 10000' are p-nitrophenyl carbonate-activated mPEGs of the indicated molecular masses conjugated with glycine.](https://figures.cochat.ai/paper-figures/f8a8191cc8f9401e9fb6bf56f5998352/control-of-hyperuricemia-in-subjects-with-refractory-gout-and-induction-of-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase I study of refractory gout, patients were treated with a PEG-uricase therapy. About one third of the treatment group, who had previously been treated with pegylated therapies at some point, had previously developed anti-PEG antibodies in the body. This resulted in lower AUC’s and poor efficacy of the PEG-uricase treatment [80].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 2×
“PEGylation has since been used to enhance the therapeutic utility of several other proteins, as well as liposomes, low-molecular-mass drugs, oligonucleotides, lipids, and polysaccharides [11].”
BackgroundMolecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Kelley's Textbook of Rheumatology
(2013) · Elsevier eBooks · doi:10.1016/c2009-1-62542-9 · Cited by 1,101
Poly(ethylene glycol): Chemistry and Biological Applications
(1997) · ACS Symposium Series · doi:10.1021/bk-1997-0680 · Cited by 646
Avramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
A specific enzyme defect in gout associated with overproduction of uric acid.
Kelley, W. N., Rosenbloom, F. M., Henderson, J. F., & Seegmiller, J. E. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.57.6.1735 · Cited by 475
Research works printed but not linked: 1
- Ganson N, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS: Antibodies to polyethylene glycol (PEG) during phase I investigation of PEG-urate oxidase (PEG-uricase; Puricase®) for refractory gout [abstract]. Arthritis Rheum. 2004, 50: s338-
Cited by
Items 101–200 of 346
Changing paradigm of prophylaxis with longer acting factor concentrates
Carcao, M. D. (2014) · Haemophilia · doi:10.1111/hae.12405 · Cited by 70
Rau, R. E., Dreyer, Z. E., Choi, M. R., Wei, L., Skowroński, R., Allamneni, K. P., Devidas, M., Raetz, E. A., Adamson, P. C., Blaney, S. M., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26873 · Cited by 70
Uricases as Therapeutic Agents to Treat Refractory Gout: Current States and Future Directions
Yang, X., Yuan, Y., Zhan, C., & Liao, F. (2012) · Drug Development Research · doi:10.1002/ddr.20493 · Cited by 69
Emerging therapies in the long‐term management of hyperuricaemia and gout
Stamp, L. K., O'Donnell, J. L., & Chapman, P. T. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01315.x · Cited by 69
Henry, C. E., Wang, Y.-Y., Yang, Q., Hoang, T., Chattopadhyay, S., Hoen, T. E., Ensign, L. M., Nunn, K. L., Schroeder, H. A., McCallen, J., et al. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.07.019 · Cited by 71
Liu, Y., Reidler, H., Pan, J., Milunic, D., Qin, D., Chen, D., Vallejo, R. P., & Yin, R. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.07.003 · Cited by 64
Therapeutic perspectives on uricases for gout
Garay, R. P., El-Gewely, M. R., Labaune, J.-P., & Richette, P. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.01.004 · Cited by 65
Chang, C.-J., Chen, C.-H., Chen, B.-M., Su, Y.-C., Chen, Y.-T., Hershfield, M. S., Lee, M.-T. M., Cheng, T.-L., Chen, Y.-T., Roffler, S. R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00622-4 · Cited by 64
Self-citationSurface Tailoring of Nanoparticles via Mixed‐Charge Monolayers and Their Biomedical Applications
Liu, X., Li, H., Jin, Q., & Ji, J. (2014) · Small · doi:10.1002/smll.201401440 · Cited by 68
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties
Nyborg, A. C., Ward, C., Zacco, A., Chacko, B. M., Grinberg, L., Geoghegan, J. C., Bean, R., Wendeler, M., Bartnik, F., O’Connor, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167935 · Cited by 63
Update on gout and hyperuricemia
Baker, J. F., & Schumacher, H. R. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02188.x · Cited by 62
Lawrence, P. B., Gavrilov, Y., Matthews, S. S., Langlois, M. I., Shental-Bechor, D., Greenblatt, H. M., Pandey, B. K., Smith, M. S., Paxman, R. J., Torgerson, C. D., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5095183 · Cited by 67
Pathogen-mimetic stealth nanocarriers for drug delivery: a future possibility
Cavadas, M. A. S., González‐Fernández, Á., & Franco, R. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.04.006 · Cited by 70
Baraf, H. S. B., Yood, R. A., Ottery, F. D., Sundy, J. S., & Becker, M. A. (2014) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000200 · Cited by 63
Self-citationGanglioside inserted into PEGylated liposome attenuates anti-PEG immunity
Mima, Y., Lila, A. S. A., Shimizu, T., Ukawa, M., Ando, H., Kurata, Y., & Ishida, T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.040 · Cited by 61
Pathophysiology, Clinical Presentation and Treatment of Gout
Teng, G. G., Nair, R., & Saag, K. G. (2006) · Drugs · doi:10.2165/00003495-200666120-00002 · Cited by 63
Subcutaneous drug delivery from nanoscale systems
Tomasini, L., Ferrere, M., & Nicolas, J. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00161-w · Cited by 71
Gaballa, S. A., Shimizu, T., Ando, H., Takata, H., Emam, S. E., Ramadan, E., Naguib, Y. W., Mady, F. M., Khaled, K. A., & Ishida, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.001 · Cited by 68
Jani, M., Isaacs, J. D., Morgan, A. W., Wilson, A. G., Plant, D., Hyrich, K. L., Chinoy, H., & Barton, A. C. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208849 · Cited by 58
Fix, S. M., Nyankima, A. G., McSweeney, M. D., Tsuruta, J. K., Lai, S. K., & Dayton, P. A. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.02.006 · Cited by 60
Polymer-enhanced biomacromolecules
Kaupbayeva, B., & Russell, A. J. (2019) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2019.101194 · Cited by 60
Injectables and Depots to Prolong Drug Action of Proteins and Peptides
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 61
Update on emerging urate-lowering therapies
Chohan, S., & Becker, M. A. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328325bd94 · Cited by 55
Enzyme therapeutics for systemic detoxification
Liu, Y., Li, J., & Lu, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.005 · Cited by 56
Leonardis, F. D., Govoni, M., Colina, M., Bruschi, M., & Trotta, F. (2007) · Rheumatology International · doi:10.1007/s00296-007-0421-7 · Cited by 54
PEGylation: Posttranslational bioengineering of protein biotherapeutics
Veronese, F. M., & Pasut, G. (2008) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2009.02.002 · Cited by 54
Immunogenicity of Polyethylene Glycol (PEG)
Garay, R. P. (2011) · The Open Conference Proceedings Journal · doi:10.2174/2210289201102010104 · Cited by 60
New advances in the treatment of gout: review of pegloticase
Reinders, M. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s6043 · Cited by 54
Burke, M. J., & Rheingold, S. R. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1213826 · Cited by 56
Khalil, A., Würthwein, G., Golitsch, J., Hempel, G., Fobker, M., Gerß, J., Möricke, A., Zimmermann, M., Smíšek, P., Zucchetti, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.258525 · Cited by 54
Polymer-mediated protein/peptide therapeutic stabilization: Current progress and future directions
Sivasankaran, R. P., Snell, K., Kunkel, G. E., Georgiou, P. G., Puente, E. G., & Maynard, H. D. (2024) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2024.101867 · Cited by 57
Rosa, R. F., Takei, K., Araújo, N. C., Loduca, S. M. A. A., Szajubok, J. C. M., & Chahade, W. H. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110201 · Cited by 49
The hope and reality of long‐acting hemophilia products
Pipe, S. W. (2012) · American Journal of Hematology · doi:10.1002/ajh.23146 · Cited by 48
Polyethylene Glycol Nanoparticles as Promising Tools for Anticancer Therapeutics
Mohapatra, A., Uthaman, S., & Park, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816963-6.00010-8 · Cited by 54
Yu, Y., Xu, W., Huang, X., Xu, X., Qiao, R., Li, Y., Han, F. Y., Peng, H., Davis, T. P., Fu, C., et al. (2020) · ACS Macro Letters · doi:10.1021/acsmacrolett.0c00291 · Cited by 51
Wen, Y., & Jawa, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.003 · Cited by 53
SITE-SPECIFIC FUNCTIONALIZATION OF PROTEINS AND THEIR APPLICATIONS TO THERAPEUTIC ANTIBODIES
van Vught, R., Pieters, R. J., & Breukink, E. J. (2014) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201402001 · Cited by 57
Self‐Assembly of Amphiphilic Block Copolypeptoids with C 2 ‐C 5 Side Chains in Aqueous Solution
Fetsch, C., Flecks, S., Gieseler, D., Marschelke, C., Ulbricht, J., PÉE, K.-H. V., & Luxenhofer, R. (2014) · Macromolecular Chemistry and Physics · doi:10.1002/macp.201400534 · Cited by 51
Uricase and other novel agents for the management of patients with treatment-failure gout
Sundy, J. S., & Hershfield, M. S. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0041-y · Cited by 47
Self-citationZhang, C., Yang, X., Yuan, Y., Pu, J., & Liao, F. (2012) · BioDrugs · doi:10.1007/bf03261880 · Cited by 47
Resolution of gouty tophi after twelve weeks of pegloticase treatment
Baraf, H. S. B., Matsumoto, A. K., Maroli, A. N., & Waltrip, R. W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23993 · Cited by 45
An update on smart biocatalysts for industrial and biomedical applications
Shakya, A. K., & Nandakumar, K. S. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0062 · Cited by 47
Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route
Takata, H., Shimizu, T., Yamade, R., Elsadek, N. E., Emam, S. E., Ando, H., Ishima, Y., & Ishida, T. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.027 · Cited by 48
Stevenson, L. F., Amaravadi, L. S., Myler, H. A., Salazar‐Fontana, L. I., Gorovits, B., Kirshner, S., Li, X., Garofolo, F., Alley, S. C., Thway, T. M., et al. (2014) · Bioanalysis · doi:10.4155/bio.14.283 · Cited by 44
Physician Awareness of Immune Responses to Polyethylene Glycol‐Drug Conjugates
McSweeney, M. D., Versfeld, Z., Carpenter, D. M., & Lai, S. K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12537 · Cited by 44
The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review
Keenan, R. T., Botson, J. K., Masri, K. R., Padnick‐Silver, L., LaMoreaux, B. D., Albert, J. A., & Pillinger, M. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.01.005 · Cited by 44
Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
Fang, J., Beland, F. A., Tang, Y., & Roffler, S. R. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.12.022 · Cited by 47
Drug and protein delivery by polymer conjugation
Grigoletto, A., Maso, K., Mero, A., Rosato, A., Schiavon, O., & Pasut, G. (2015) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.08.006 · Cited by 45
Effect of Molecular Architecture on Cell Interactions and Stealth Properties of PEG
Özer, İ., Tomak, A., Zareie, H. M., Baran, Y., & Bulmuş, V. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00443 · Cited by 43
Gulati, N. M., Pitek, A. S., Czapar, A. E., Stewart, P. L., & Steinmetz, N. F. (2018) · Journal of Materials Chemistry B · doi:10.1039/c7tb03106h · Cited by 43
Hausmann, O. V., Daha, M. R., Longo, N., Knol, E. F., Müller, I., Northrup, H., & Brockow, K. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.05.006 · Cited by 41
Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture
Lin, Y., Chen, B., Tran, T. T. M., Chang, T.-C., Al‐Qaisi, T. S., & Roffler, S. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.021 · Cited by 44
Sylvestre, M., Lv, S., Yang, L. F., Luera, N., Peeler, D. J., Chen, B., Roffler, S. R., & Pun, S. H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.015 · Cited by 43
Streptomyces-based cell factories for production of biomolecules and bioactive metabolites
El‐Naggar, N. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821477-0.00011-8 · Cited by 51
Scomparin, A., Florindo, H. F., Tiram, G., Ferguson, E. L., & Satchi‐Fainaro, R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.011 · Cited by 39
Gámez, A., Wang, L., Sarkissian, C. N., Wendt, D., Fitzpatrick, P., Lemontt, J. F., Scriver, C. R., & Stevens, R. C. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.04.015 · Cited by 39
Extended Half-Life (EHL) Coagulation Factors: A New Era in the Management of Haemophilia Patients
Ar, M. C., Balkan, C., & Kavaklı, K. (2019) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2019.2018.0393 · Cited by 39
Miller, T., Hill, A., Uezguen, S., Weigandt, M., & Goepferich, A. (2012) · Biomacromolecules · doi:10.1021/bm3002045 · Cited by 37
The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes
Grenier, P., Chénard, V., & Bertrand, N. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.005 · Cited by 38
Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand
Na, S. J., Chae, S. Y., Lee, S., Park, K., Kim, K., Park, J. H., Kwon, I. C., Jeong, S. Y., & Lee, K. C. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.013 · Cited by 38
Poppenborg, S. M., Wittmann, J., Walther, W., Brandenburg, G., Krähmer, R., Baumgart, J., & Leenders, F. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.06.007 · Cited by 35
El‐Naggar, N. E., Haroun, S. A., El-Weshy, E. M., Metwally, E. A., & Sherief, A.-D. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-49201-1 · Cited by 35
Kyluik‐Price, D. L., Li, L., & Scott, M. D. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.016 · Cited by 35
Myler, H. A., Hruska, M. W., Srinivasan, S., Cooney, E. L., Kong, G., Dodge, R. W., Krishna, M., Zhu, J., Felix, T., Gleason, C. R., et al. (2015) · Bioanalysis · doi:10.4155/bio.15.36 · Cited by 34
Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids
Vanderschuren, K., Arranz‐Gibert, P., Khang, M., Dagan, H., Gaudin, A., Yang, F., Folta‐Stogniew, E. J., Saltzman, W. M., Amiram, M., & Isaacs, F. J. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103099119 · Cited by 36
PEGylated drugs in rheumatology--why develop them and do they work?
McDonnell, T. C. R., Ioannou, Y., & Rahman, A. (2013) · Rheumatology · doi:10.1093/rheumatology/ket278 · Cited by 34
Management of Gout in Older Adults
Hoskison, K. T., & Wortmann, R. L. (2007) · Drugs & Aging · doi:10.2165/00002512-200724010-00002 · Cited by 34
Humphries, J., Pizzi, D., Sonderegger, S., Fletcher, N. L., Houston, Z. H., Bell, C. A., Kempe, K., & Thurecht, K. J. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00765 · Cited by 33
Weaving Enzymes with Polymeric Shells for Biomedical Applications
Li, M., Blum, N. T., Wu, J., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202008438 · Cited by 35
Elliott, V. L., Edge, G. T., Phelan, M. M., Lian, L., Webster, R., Finn, R. F., Park, B. K., & Kitteringham, N. R. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200587m · Cited by 33
PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation
Tian, H., Yuan, G., Gao, X., & Yao, W. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01575.x · Cited by 32
Lin, W., Zhang, H., Wu, J., Wang, Z., Sun, H., Yuan, J., & Chen, S. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb00474k · Cited by 31
Pegloticase: A Novel Agent for Treatment-Refractory Gout
Shannon, J. A., & Cole, S. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q593 · Cited by 31
Zhang, C., Fan, K. C., Ma, X., & Wei, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039659 · Cited by 35
Management of Hyperuricemia and Gout in CKD
Gaffo, A., & Saag, K. G. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.035 · Cited by 33
Chang, T.-C., Chen, B., Lin, W.-W., Yu, P., Chiu, Y., Chen, Y.-T., Wu, J., Cheng, T., Hwang, D., & Roffler, S. R. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics12010015 · Cited by 31
Enhanced Biocompatibility of Polyampholyte Hydrogels
Haag, S. L., & Bernards, M. T. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c00114 · Cited by 28
Özer, İ., Slezak, A., Sirohi, P., Li, X., Zakharov, N., Yao, Y., Everitt, J. I., Spasojević, I., Craig, S. L., Collier, J. H., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2022.121985 · Cited by 28
Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities
Wang, H., Lin, S., Wu, X., Jiang, K., Lu, H., & Zhan, C. (2023) · Advanced Science · doi:10.1002/advs.202301777 · Cited by 39
Lila, A. S. A., Ichihara, M., Shimizu, T., Ishida, T., & Kiwada, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00562 · Cited by 31
Toro-Montoya, A. I., Paiva, M., Ackerley, C. A., & Grunebaum, E. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2006.07.003 · Cited by 29
PEGylated Systems in Pharmaceutics
Porfiryeva, N. N., Moustafine, R. I., & Khutoryanskiy, V. V. (2020) · Polymer Science Series C · doi:10.1134/s181123822001004x · Cited by 31
Zhou, P., Li, Z., & Chau, Y. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.07.014 · Cited by 27
Elsadek, N. E., Hondo, E., Shimizu, T., Takata, H., Lila, A. S. A., Emam, S. E., Ando, H., Ishima, Y., & Ishida, T. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00366 · Cited by 30
Yue, C. S., Huang, W. J.-S., Alton, M., Maroli, A. N., Waltrip, R. W., Wright, D. D., & Marco, M. P. D. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008317589 · Cited by 27
Mineralized cyclodextrin nanoparticles for sustained protein delivery
Sivasubramanian, M., Thambi, T., & Park, J. H. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2013.05.018 · Cited by 27
Chang, T.-C., Chen, B., Wu, J.-Y., Cheng, T., & Roffler, S. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112502 · Cited by 27
Update on the management of hyperuricemia and gout.
Pillinger, M. H., & Keenan, R. T. (2008) · PubMed · Cited by 26
Anderson, A., & Singh, J. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008335.pub2 · Cited by 25
Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics
Gorovits, B., Peng, K., & Kromminga, A. (2019) · BioDrugs · doi:10.1007/s40259-019-00389-8 · Cited by 25
New developments in clinically relevant mechanisms and treatment of hyperuricemia
Lee, S. H., & Terkeltaub, R. A. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-996-0029-z · Cited by 25
Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine
Shen, L., Li, Z., Ma, A. L., Cruz-Teran, C. A., Talkington, A., Shipley, S. T., & Lai, S. K. (2024) · ACS Nano · doi:10.1021/acsnano.3c11165 · Cited by 25
Upgrading biomaterials with synthetic biological modules for advanced medical applications
Wagner, H. J., Sprenger, A., Rebmann, B., & Weber, W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.004 · Cited by 27
Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats
Fang, J., Vanlandingham, M. M., Beland, F. A., Felton, R. P., Maisha, M. P., Olson, G. R., Patton, R. E., Rosenberg, A. S., & da Costa, G. G. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.01.011 · Cited by 27
Tratamiento de la gota: reflexiones desde el estudio GEMA
Pérez-Ruiz, F. (2008) · Reumatología Clínica · doi:10.1016/s1699-258x(08)76167-9 · Cited by 23
Fletcher, A. M., Tellier, P., Douville, J., Mansell, P., Graziano, M. J., Mangipudy, R. S., Brodie, T. A., & Achanzar, W. E. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.09.023 · Cited by 27
Tesařová, B., Dostálová, S., Šmídová, V., Goliášová, Z., Škubalová, Z., Michalkova, H., Hynek, D., Michálek, P., Polanska, H. H., Vaculovičová, M., et al. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.100501 · Cited by 23
Immunological responses to PEGylated proteins
Elsadek, N. E., Lila, A. S. A., & Ishida, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64081-9.00005-x · Cited by 34
Immunogenicity Risk Assessment for PEGylated Therapeutics
Mora, J. R., White, J. T., & DeWall, S. L. (2020) · The AAPS Journal · doi:10.1208/s12248-020-0420-0 · Cited by 25
Dirauf, M., Grune, C., Weber, C., Schubert, U. S., & Fischer, D. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.109801 · Cited by 22
Metadata
- Authors
- Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Hershfield, Michael S
- Venue
- Arthritis Research & Therapy
- Published
- 2005-12-02
- Volume
- 8
- Issue
- 1
- Pages
- R12-R12
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC1526556
- OpenAlex
- W1918944513
- Cited by
- 350
- References
- 40
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 14 · 2023: 13 · 2022: 13 · 2021: 16 · 2020: 27 · 2019: 24 · 2018: 18 · 2017: 11 · 2016: 20 · 2015: 11 · 2014: 22 · 2013: 17 · 2012: 28
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Savient Pharmaceuticals
- National Institutes of Health (MO1-RR-30, RR-30)
- National Center for Research Resources (M01 RR 30, MO 1 RR-30)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- refractory gout, hyperuricemia, tophaceous gout, anti-PEG antibodies, subcutaneous injection, gout flares, injection site reactions
- MeSH terms
- Adult, Aged, Carbon Radioisotopes, Female, Gout, Humans, Immunoglobulin G, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Urate Oxidase, Urea, Uric Acid, Hyperuricemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.